13 - 14 November, 2019 | Hilton Munich City, Munich, Germany

Main Conference Day 1

8:30 am - 9:00 am Registration and Coffee

9:00 am - 9:10 am Chairman's Opening Remarks

9:10 am - 9:30 am Speed Networking

A highlight of Pharma IQ events! Be ready to meet your peers and share best practices. You will have several 2 minute conversations to enable you to introduce yourself to your peers. There is a prize in it for the winner, so, get networking!

Please Share:
1. Who you are
2. The scope of your job role
3. What you plan to achieve from attending this event
4. Your #1 challenge

9:30 am - 10:10 am THE EUROPEAN HEALTH DATA & EVIDENCE NETWORK: THE FIRST YEAR IN EHDEN

  • Gain insight on EHDEN, the EU IMI2 project developing at scale infrastructure for an open science research community in Europe
  • Discover how EHDEN is working on research use cases for validation, as well as in collaboration with the European Medicines Agency, from drug utilisation through to HTA and treatment outcomes
  • Explore the first of five years of the project, its initial progress and the potential for the remainder of the project in supporting 21st century research with 21st century tools
Nigel Hughes, Scientific Director at Janssen

Nigel Hughes

Scientific Director
Janssen

10:10 am - 10:40 am Networking Coffee Break

10:40 am - 11:20 am APPLYING AN END-TO-END APPROACH TO BREAK DOWN DATA SILOS IN DRUG DISCOVERY AND DEVELOPMENT

  • Set expectations and change the mind-set of your organisation by showing the value of data infrastructure and advanced analytics
  • Focus your strategy beyond the next year and apply this to the next stage of development
  • Look at data curation as the future of analytics and use this as a driver for technical investment
Wolfgang Paul, Principal Scientist Digitalisation Lead in Large Molecule Research at Roche

Wolfgang Paul

Principal Scientist Digitalisation Lead in Large Molecule Research
Roche

11:20 am - 12:00 pm AI IN IMPROVING THE EFFICIENCY OF PHARMACEUTICAL R&D: REALITY AND HYPE

  • Learn how CADD and automation are used to provide accurate and reliable data
  • Identify the current regulatory trend of shifting from data-based filings to information-based filings
  • Understand how data analysis is converted to information
Gopal Karemore, Principal Data Scientist at Novo Nordisk

Gopal Karemore

Principal Data Scientist
Novo Nordisk

12:00 pm - 1:00 pm Networking Lunch

Use this opportunity to benchmark with your peers and identify the key strategies required to optimise your data strategy and boost its efficiency. Choose one round table and after 30 minutes rotate round to another topic area of discussion.
  • Applying an End-to-End Approach to Break Down Data Silos in Drug Development and Discovery
  • Interpreting Complex Real World Data for Pharmaceutical Research
  • AI in Improving the Efficiency of Pharmaceutical R&D: Reality and Hype
Wolfgang Paul, Principal Scientist Digitalisation Lead in Large Molecule Research at Roche

Wolfgang Paul

Principal Scientist Digitalisation Lead in Large Molecule Research
Roche

Paul Agapow, Health Informatics Director at AstraZeneca

Paul Agapow

Health Informatics Director
AstraZeneca

Gopal Karemore, Principal Data Scientist at Novo Nordisk

Gopal Karemore

Principal Data Scientist
Novo Nordisk

2:00 pm - 2:40 pm INTERPRETING COMPLEX REAL WORLD DATA FOR PHARMACEUTICAL RESEARCH

  • Identify why costs, data availability and the need for statistical power are making RWD increasingly attractive for research
  • Learn best practices to navigate complex, variable and noisy records
  • Explore and analyse longitudinal data for patient subtype analysis
Paul Agapow, Health Informatics Director at AstraZeneca

Paul Agapow

Health Informatics Director
AstraZeneca

2:40 pm - 3:10 pm Networking Coffee Break

3:10 pm - 3:50 pm CASE STUDY: EXPLOITING OBSERVATIONAL DATA TO SUPPORT DEVELOPMENT OF OBESITY DRUGS

  • Predict risks of health outcomes associated with obesity
  • Utilise observational data to understand your target population
  • Manage stakeholders’ expectations when introducing observational data
Volker Schnecke, Big Data Analytic Specialist at Novo Nordisk

Volker Schnecke

Big Data Analytic Specialist
Novo Nordisk

3:50 pm - 4:30 pm TRENDS IN DATA ANALYTICS: FROM GENERAL INDUSTRY TRENDS TO IMPLICATIONS IN BIOPROCESSING

  • Discuss industry 4.0 and the impact of data analytics, and identify new user communities to address
  • Analyse expectations regarding user interface (UI) design and user experience (UX)
  • Look at innovative approaches in Bioprocess Data Management & Analytics: PAT 4.0
Stefan Rannar, Product Manager, SIMCA at Sartorius Stedim Data Analytics

Stefan Rannar

Product Manager, SIMCA
Sartorius Stedim Data Analytics

4:30 pm - 5:10 pm THE WHY? THE WHAT? THE HOW?

  • Uncover an HEOR perspective on data & analytics that makes a difference for market access in speciality care
  • Look at why data is needed, the types of data needed and consider, what about patient’s voice?
  • Identify how is the data obtained, analyzed, and used for market access
Asif Khan, Global HEOR Evidence Expert Lead at Sanofi

Asif Khan

Global HEOR Evidence Expert Lead
Sanofi

5:10 pm - 5:10 pm Chairman's Summary and End of Day One